Press

PsyBio Therapeutics Reports Third Quarter 2022 Financial Results

Nov 29 • 2 min read

PsyBio Therapeutics Corp. (TSXV: PSYB | OTCQB: PSYBF), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announced that it has reported its unaudited interim financial results for the three and nine month period ended September 30,…

Core One Labs’ Announces Appointment of BF Borgers CPA PC as Its New Auditor

Nov 28 • 2 min read

Core One Labs Inc. (CSE: COOL | OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) – Further to its news release dated September 29, 2022, the Company is pleased to announce the appointment BF Borgers CPA PC (‘BF Borgers’ or the ‘Successor Auditor’) as its new auditor effective as of November 23, 2022. BF Borgers replaces Dale Matheson Carr-Hilton Labonte LLP (‘DMCL’…

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 28 • 4 min read

Bright Minds Biosciences Inc. (CSE:DRUG | NASDAQ:DRUG) is pleased to announce a non-brokered private placement of (i) pre-funded warrants of the Company at a price of $1.249 per PFW, and (ii) units of the Company at a price of $1.25 per Unit.The aggregate minimum gross proceeds of the Unit Offering and the PFW Offering, on…

Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call

Nov 28 • 2 min read

Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, announced today that it now plans to release financial results for its fiscal 2023 second quarter for the three-month period ended September 30, 2022, after market close on Tuesday, November 29, 2022. The Company will conduct a conference…

Albert Labs Announces Private Placement

Nov 27 • 3 min read

Albert Labs International Corp. [CSE: ABRT | FSE: VB50], a biopharmaceutical drug discovery company focused on gaining regulatory approval for active compounds to treat various mental health conditions, has announced a non-brokered private placement for gross proceeds of up to $3,000,000 (the “Offering”), with the first tranche raised at a price of CAD $0.08 per…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441